TLSI
insider transactionsTriSalus Life Sciences, Inc. — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
Cluster buy signal: Multiple insiders at the same company buying around the same time — often a stronger signal than a single buy. 6 different insiders made open-market purchases in the last 365 days, totalling $3.6M.
Net shares · 365d
+1.1M
1.2M buy · 34.2K sell
Net value · 365d
$3.5M
$3.6M in · $135.8K out
Sentiment · 365d
Net buying
96% buying · 4% selling
Open-market trades · 365d
27
1.2M buy · 34.2K sell
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
All transactions
-
Buy·P
Director
$151.8K
60.0K sh · $2.53
Own +69%
-
Buy·P
Mary T Szela KEY
CEO and President
$102.8K
39.7K sh · $2.59
Own +4%
-
Buy·P
Director
$500.0K
200.0K sh · $2.50
Own +100%
-
Buy·P
Director
$1.0M
410.0K sh · $2.50
Own +49%
-
Buy·P
David Patience KEY
Chief Financial Officer
$17.3K
7.1K sh · $2.43
Own +3%
-
Buy·P
Director
$24.6K
10.0K sh · $2.46
Own +16%
-
Sell·S
Chief Commercial Officer
$1.4K
543 sh · $2.67
Own -0%
-
Grant·A
Director
$0
75.2K sh
Own +37%
-
Grant·A
Director
$0
34.2K sh
Own +64%
-
Grant·A
Director
$0
37.6K sh
Own +239%
-
Grant·A
Director
$0
56.4K sh
Own +100%
-
Grant·A
Director
$0
24.6K sh
Own +42%
-
Grant·A
Director
$0
28.2K sh
Own +93%
-
Grant·A
Director
$0
47.0K sh
Own +51%
-
Grant·A
Director
$0
20.1K sh
Own +2%
-
Grant·A
Director
$0
23.5K sh
Own +3%
-
Grant·A
Director
$0
56.4K sh
Own +87%
-
Grant·A
Director
$0
23.1K sh
Own +2%
-
Grant·A
Director
$0
28.2K sh
Own +2%
-
Grant·A
Director
$0
56.4K sh
Own +63%
-
Grant·A
Director
$0
28.2K sh
Own +5%
-
Grant·A
Director
$0
56.4K sh
Own +100%
-
Grant·A
Director
$0
24.6K sh
Own +65%
-
Grant·A
Director
$0
28.2K sh
Own +289%
-
Sell·S
Mary T Szela KEY
CEO and President
$61.4K
15.9K sh · $3.85
Own -2%
-
Sell·S
Chief Regulatory Officer
$3.2K
774 sh · $4.12
Own -1%
-
Sell·S
Chief Commercial Officer
$1.7K
419 sh · $4.12
Own -0%
-
Sell·S
Chief of Clinical Operations
$1.1K
273 sh · $4.12
Own -0%
-
Sell·S
Chief of Research
$2.4K
579 sh · $4.12
Own -0%
-
Sell·S
Chief Regulatory Officer
$6.3K
1.6K sh · $4.09
Own -1%
-
Sell·S
Chief Commercial Officer
$6.5K
1.6K sh · $4.09
Own -1%
-
Sell·S
Chief of Clinical Operations
$7.2K
1.8K sh · $4.09
Own -2%
-
Sell·S
Chief of Research
$6.0K
1.5K sh · $4.09
Own -1%
-
Sell·S
Mary T Szela KEY
CEO and President
$18.0K
4.4K sh · $4.13
Own -1%
-
Sell·S
Chief Regulatory Officer
$5.0K
1.2K sh · $4.13
Own -1%
-
Sell·S
Chief Commercial Officer
$6.0K
1.4K sh · $4.13
Own -1%
-
Sell·S
Chief of Clinical Operations
$4.8K
1.2K sh · $4.13
Own -1%
-
Sell·S
Chief of Research
$4.7K
1.1K sh · $4.13
Own -1%
-
Buy·P
Director
$125.0K
30.5K sh · $4.10
Own New
-
Buy·P
Mary T Szela KEY
CEO and President
$125.0K
30.5K sh · $4.10
Own +4%
-
Buy·P
Director
$480.5K
117.2K sh · $4.10
Own +142%
-
Buy·P
Director
$1000.0K
243.9K sh · $4.10
Own +45%
-
Buy·P
David Patience KEY
Chief Financial Officer
$15.0K
3.7K sh · $4.10
Own +1%
-
Buy·P
Director
$40.0K
9.8K sh · $4.10
Own New
-
Grant·A
Director
$0
92.5K sh
Own New
-
Exercise·C
Director
$0
100.0K sh
Own New
-
Exercise·C
Director
$0
330.0K sh
Own +35%
-
Exercise·C
10% Owner
$0
230.0K sh
Own New
-
Exercise·C
10% Owner
$0
759.0K sh
Own +12%
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| May 15, 2026 | Mats Wahlstrom | Buy P | 60.0K | $151.8K |
| May 15, 2026 | Mary T Szela KEY | Buy P | 39.7K | $102.8K |
| May 15, 2026 | Stansky Michael P | Buy P | 200.0K | $500.0K |
| May 15, 2026 | Stansky Michael P | Buy P | 410.0K | $1.0M |
| May 15, 2026 | David Patience KEY | Buy P | 7.1K | $17.3K |
| May 15, 2026 | Gary B. Gordon | Buy P | 10.0K | $24.6K |
| May 15, 2026 | Richard Marshak | Sell S | 543 | $1.4K |
| May 14, 2026 | Mats Wahlstrom | Grant A | 75.2K | $0 |
| May 14, 2026 | Mats Wahlstrom | Grant A | 34.2K | $0 |
| May 14, 2026 | Mats Wahlstrom | Grant A | 37.6K | $0 |
| May 14, 2026 | William Valle | Grant A | 56.4K | $0 |
| May 14, 2026 | William Valle | Grant A | 24.6K | $0 |
| May 14, 2026 | William Valle | Grant A | 28.2K | $0 |
| May 14, 2026 | Stansky Michael P | Grant A | 47.0K | $0 |
| May 14, 2026 | Stansky Michael P | Grant A | 20.1K | $0 |
| May 14, 2026 | Stansky Michael P | Grant A | 23.5K | $0 |
| May 14, 2026 | David J Matlin | Grant A | 56.4K | $0 |
| May 14, 2026 | David J Matlin | Grant A | 23.1K | $0 |
| May 14, 2026 | David J Matlin | Grant A | 28.2K | $0 |
| May 14, 2026 | Kerry R Hicks | Grant A | 56.4K | $0 |
| May 14, 2026 | Kerry R Hicks | Grant A | 28.2K | $0 |
| May 14, 2026 | Gary B. Gordon | Grant A | 56.4K | $0 |
| May 14, 2026 | Gary B. Gordon | Grant A | 24.6K | $0 |
| May 14, 2026 | Gary B. Gordon | Grant A | 28.2K | $0 |
| Mar 17, 2026 | Mary T Szela KEY | Sell S | 15.9K | $61.4K |
| Mar 16, 2026 | Jennifer Stevens | Sell S | 774 | $3.2K |
| Mar 16, 2026 | Richard Marshak | Sell S | 419 | $1.7K |
| Mar 16, 2026 | Jodi Devlin | Sell S | 273 | $1.1K |
| Mar 16, 2026 | Bryan F. Cox | Sell S | 579 | $2.4K |
| Mar 12, 2026 | Jennifer Stevens | Sell S | 1.6K | $6.3K |
| Mar 12, 2026 | Richard Marshak | Sell S | 1.6K | $6.5K |
| Mar 12, 2026 | Jodi Devlin | Sell S | 1.8K | $7.2K |
| Mar 12, 2026 | Bryan F. Cox | Sell S | 1.5K | $6.0K |
| Mar 11, 2026 | Mary T Szela KEY | Sell S | 4.4K | $18.0K |
| Mar 11, 2026 | Jennifer Stevens | Sell S | 1.2K | $5.0K |
| Mar 11, 2026 | Richard Marshak | Sell S | 1.4K | $6.0K |
| Mar 11, 2026 | Jodi Devlin | Sell S | 1.2K | $4.8K |
| Mar 11, 2026 | Bryan F. Cox | Sell S | 1.1K | $4.7K |
| Feb 23, 2026 | William Valle | Buy P | 30.5K | $125.0K |
| Feb 23, 2026 | Mary T Szela KEY | Buy P | 30.5K | $125.0K |
| Feb 23, 2026 | Stansky Michael P | Buy P | 117.2K | $480.5K |
| Feb 23, 2026 | Stansky Michael P | Buy P | 243.9K | $1000.0K |
| Feb 23, 2026 | David Patience KEY | Buy P | 3.7K | $15.0K |
| Feb 23, 2026 | Gary B. Gordon | Buy P | 9.8K | $40.0K |
| Feb 4, 2026 | Stansky Michael P | Grant A | 92.5K | $0 |
| Jul 31, 2025 | David J Matlin | Exercise C | 100.0K | $0 |
| Jul 31, 2025 | David J Matlin | Exercise C | 330.0K | $0 |
| Jul 31, 2025 | Equity Ab Frankenius | Exercise C | 230.0K | $0 |
| Jul 31, 2025 | Equity Ab Frankenius | Exercise C | 759.0K | $0 |
About TLSI insider trading
This page tracks insider transactions for TriSalus Life Sciences, Inc. (TLSI) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.